Divarasib

Roche, KRAS inhibitor, KRAS mutation, Amgen, Mirati Therapeutics, Divarasib, NSCLC

Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain

Anika Sharma

Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...